Product: Phospho-EGFR (Tyr1173)[Tyr1197] Antibody
Catalog: AF3048
Description: Rabbit polyclonal antibody to Phospho-EGFR (Tyr1173)[Tyr1197]
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit
Mol.Wt.: 175kDa; 134kD(Calculated).
Uniprot: P00533
RRID: AB_2834475

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%)
Clonality:
Polyclonal
Specificity:
Phospho-EGFR (Tyr1173) Antibody detects endogenous levels of EGFR only when phosphorylated at Tyr1197, which site historically referenced as Tyr1173.
RRID:
AB_2834475
Cite Format: Affinity Biosciences Cat# AF3048, RRID:AB_2834475.
Conjugate:
Unconjugated.
Purification:
The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

Avian erythroblastic leukemia viral (v erb b) oncogene homolog; Cell growth inhibiting protein 40; Cell proliferation inducing protein 61; EGF R; EGFR; EGFR_HUMAN; Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog); Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian); Epidermal growth factor receptor; erb-b2 receptor tyrosine kinase 1; ERBB; ERBB1; Errp; HER1; mENA; NISBD2; Oncogen ERBB; PIG61; Proto-oncogene c-ErbB-1; Receptor tyrosine protein kinase ErbB 1; Receptor tyrosine-protein kinase ErbB-1; SA7; Species antigen 7; Urogastrone; v-erb-b Avian erythroblastic leukemia viral oncogen homolog; wa2; Wa5;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
P00533 EGFR_HUMAN:

Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

Description:
EGFR is a receptor tyrosine kinase. Receptor for epidermal growth factor (EGF) and related growth factors including TGF-alpha, amphiregulin, betacellulin, heparin-binding EGF-like growth factor, GP30 and vaccinia virus growth factor. Is involved in the control of cell growth and differentiation.
Sequence:
MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEVVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALAVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDFQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGCTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYVVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFKNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAFENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKLFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCNLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVMGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTEDSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLNTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRVAPQSSEFIGA

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Rabbit
100
Xenopus
71
Dog
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P00533 As Substrate

Site PTM Type Enzyme
K37 Sumoylation
N73 N-Glycosylation
S77 Phosphorylation
Y88 Phosphorylation
Y112 Phosphorylation
Y113 Phosphorylation
Y117 Phosphorylation
N128 N-Glycosylation
K133 Acetylation
S151 Phosphorylation
N175 N-Glycosylation
C190 S-Nitrosylation
N196 N-Glycosylation
K212 Ubiquitination
R222 Methylation
R224 Methylation
S229 Phosphorylation P31749 (AKT1)
K284 Acetylation
T290 Phosphorylation
C291 S-Nitrosylation
K293 Ubiquitination
C311 S-Nitrosylation
C329 S-Nitrosylation
K346 Acetylation
N352 N-Glycosylation
T354 Phosphorylation
N361 N-Glycosylation
K396 Ubiquitination
N413 N-Glycosylation
N444 N-Glycosylation
S457 Phosphorylation
C470 S-Nitrosylation
K479 Ubiquitination
K487 Ubiquitination
K489 Ubiquitination
S492 Phosphorylation
S511 Phosphorylation
N528 N-Glycosylation
K538 Ubiquitination
N568 N-Glycosylation
Y585 Phosphorylation
N603 N-Glycosylation
N623 N-Glycosylation
S645 Phosphorylation
T648 Phosphorylation
T678 Phosphorylation Q16512 (PKN1) , P17252 (PRKCA) , Q15139 (PRKD1) , Q6P5Z2 (PKN3)
T693 Phosphorylation P28482 (MAPK1) , P27361 (MAPK3) , Q16539 (MAPK14) , Q15139 (PRKD1)
S695 Phosphorylation
K708 Ubiquitination
K713 Ubiquitination
K714 Ubiquitination
K716 Ubiquitination
S720 Phosphorylation
T725 Phosphorylation
Y727 Phosphorylation P12931 (SRC)
K728 Ubiquitination
K737 Ubiquitination
K739 Ubiquitination
K745 Methylation
K745 Ubiquitination
S752 Phosphorylation
K754 Ubiquitination
K757 Ubiquitination
Y764 Phosphorylation P12931 (SRC)
S768 Phosphorylation Q9UQM7 (CAMK2A)
T790 Phosphorylation
Y801 Phosphorylation
K823 Ubiquitination
Y827 Phosphorylation
K846 Ubiquitination
K852 Ubiquitination
K860 Ubiquitination
K867 Ubiquitination
Y869 Phosphorylation P00533 (EGFR) , P12931 (SRC) , Q13882 (PTK6)
K875 Ubiquitination
Y891 Phosphorylation
T892 Phosphorylation Q13131 (PRKAA1)
K913 Ubiquitination
Y915 Phosphorylation P12931 (SRC)
K929 Ubiquitination
T940 Phosphorylation
Y944 Phosphorylation P12931 (SRC)
K960 Ubiquitination
K970 Ubiquitination
Y978 Phosphorylation
S991 Phosphorylation
T993 Phosphorylation
S995 Phosphorylation
Y998 Phosphorylation P00533 (EGFR)
Y1016 Phosphorylation P12931 (SRC) , P00519 (ABL1) , P00533 (EGFR)
S1025 Phosphorylation
S1026 Phosphorylation P06493 (CDK1)
S1028 Phosphorylation
S1030 Phosphorylation
T1032 Phosphorylation
S1037 Phosphorylation
S1039 Phosphorylation Q16539 (MAPK14) , Q15759 (MAPK11)
T1041 Phosphorylation Q15759 (MAPK11) , Q16539 (MAPK14)
S1042 Phosphorylation
S1045 Phosphorylation
T1046 Phosphorylation
S1057 Phosphorylation
K1061 Acetylation
K1061 Ubiquitination
S1064 Phosphorylation Q9UQM7 (CAMK2A)
Y1069 Phosphorylation P00533 (EGFR)
S1070 Phosphorylation Q9UQM7 (CAMK2A)
S1071 Phosphorylation Q13555 (CAMK2G) , Q9UQM7 (CAMK2A)
T1074 Phosphorylation
T1078 Phosphorylation
S1081 Phosphorylation Q9UQM7 (CAMK2A)
T1085 Phosphorylation
Y1092 Phosphorylation O60674 (JAK2) , P00519 (ABL1) , P00533 (EGFR)
S1096 Phosphorylation
K1099 Ubiquitination
S1104 Phosphorylation
Y1110 Phosphorylation P12931 (SRC) , P00533 (EGFR)
S1120 Phosphorylation Q9UQM7 (CAMK2A)
Y1125 Phosphorylation P12931 (SRC)
S1130 Phosphorylation
T1131 Phosphorylation
Y1138 Phosphorylation P00533 (EGFR)
T1141 Phosphorylation
T1145 Phosphorylation
T1150 Phosphorylation
S1153 Phosphorylation
K1160 Ubiquitination
S1162 Phosphorylation
S1166 Phosphorylation Q9UQM7 (CAMK2A)
Y1172 Phosphorylation P00519 (ABL1) , P00533 (EGFR) , P12931 (SRC)
K1179 Acetylation
K1179 Ubiquitination
K1182 Acetylation
K1182 Ubiquitination
K1188 Acetylation
K1188 Methylation
K1188 Ubiquitination
S1190 Phosphorylation
T1191 Phosphorylation
Y1197 Phosphorylation P00519 (ABL1) , P00533 (EGFR)
R1199 Methylation

PTMs - P00533 As Enzyme

Substrate Site Source
O14828-1 (SCAMP3) Y41 Uniprot
O14939-1 (PLD2) Y179 Uniprot
O14939 (PLD2) Y296 Uniprot
O14964 (HGS) Y329 Uniprot
O14964 (HGS) Y334 Uniprot
O15126-1 (SCAMP1) Y37 Uniprot
O15455 (TLR3) Y858 Uniprot
O15492 (RGS16) Y168 Uniprot
O15492 (RGS16) Y177 Uniprot
O60716 (CTNND1) Y228 Uniprot
O75886-1 (STAM2) Y192 Uniprot
O95477 (ABCA1) S2054 Uniprot
P00533 (EGFR) Y869 Uniprot
P00533 (EGFR) Y998 Uniprot
P00533 (EGFR) Y1016 Uniprot
P00533 (EGFR) Y1069 Uniprot
P00533 (EGFR) Y1092 Uniprot
P00533 (EGFR) Y1110 Uniprot
P00533 (EGFR) Y1138 Uniprot
P00533-1 (EGFR) Y1172 Uniprot
P00533 (EGFR) Y1197 Uniprot
P04083 (ANXA1) Y21 Uniprot
P04626-5 (ERBB2) Y1218 Uniprot
P04626 (ERBB2) Y1248 Uniprot
P07948 (LYN) Y32 Uniprot
P09211 (GSTP1) Y4 Uniprot
P09211 (GSTP1) Y8 Uniprot
P09211 (GSTP1) Y199 Uniprot
P0DP23 (CALM1) Y100 Uniprot
P11171-4 (EPB41) Y418 Uniprot
P11171-3 (EPB41) Y437 Uniprot
P11171 (EPB41) Y660 Uniprot
P12004 (PCNA) Y211 Uniprot
P14618 (PKM) Y148 Uniprot
P15311 (EZR) Y146 Uniprot
P15311 (EZR) Y354 Uniprot
P15941-7 (MUC1) Y229 Uniprot
P15941-11 (MUC1) Y238 Uniprot
P15941-8 (MUC1) Y247 Uniprot
P15941 (MUC1) Y1229 Uniprot
P18031 (PTPN1) Y66 Uniprot
P19174 (PLCG1) Y472 Uniprot
P19174-2 (PLCG1) Y771 Uniprot
P19174 (PLCG1) Y783 Uniprot
P19174 (PLCG1) Y1253 Uniprot
P20936-2 (RASA1) Y283 Uniprot
P20936 (RASA1) Y460 Uniprot
P21860 (ERBB3) Y1276 Uniprot
P21860 (ERBB3) Y1289 Uniprot
P22681 (CBL) Y371 Uniprot
P22681 (CBL) Y700 Uniprot
P22681 (CBL) Y731 Uniprot
P22681 (CBL) Y774 Uniprot
P24844 (MYL9) Y143 Uniprot
P24844 (MYL9) Y156 Uniprot
P25098 (GRK2) Y13 Uniprot
P25098 (GRK2) Y86 Uniprot
P25098 (GRK2) Y92 Uniprot
P29353-3 (SHC1) Y194 Uniprot
P29353-3 (SHC1) Y195 Uniprot
P29353-2 (SHC1) Y239 Uniprot
P29353-2 (SHC1) Y240 Uniprot
P29353-3 (SHC1) Y272 Uniprot
P29353-2 (SHC1) Y317 Uniprot
P30530 (AXL) Y779 Uniprot
P35222 (CTNNB1) Y142 Uniprot
P35222 (CTNNB1) Y654 Uniprot
P37231-2 (PPARG) Y74 Uniprot
P42224-1 (STAT1) Y701 Uniprot
P42566-1 (EPS15) Y849 Uniprot
P46108 (CRK) Y221 Uniprot
P48050 (KCNJ4) Y234 Uniprot
P51692 (STAT5B) Y699 Uniprot
P51692 (STAT5B) Y725 Uniprot
P51692 (STAT5B) Y740 Uniprot
P51692 (STAT5B) Y743 Uniprot
P52735 (VAV2) Y142 Uniprot
P52735 (VAV2) Y159 Uniprot
P52735 (VAV2) Y172 Uniprot
P61925 (PKIA) Y8 Uniprot
P62993-2 (GRB2) Y168 Uniprot
P62993 (GRB2) Y209 Uniprot
P67775 (PPP2CA) Y307 Uniprot
Q05397 (PTK2) Y5 Uniprot
Q05397 (PTK2) Y194 Uniprot
Q05655 (PRKCD) Y313 Uniprot
Q05655 (PRKCD) Y334 Uniprot
Q13315 (ATM) Y370 Uniprot
Q13480-2 (GAB1) Y285 Uniprot
Q13480-2 (GAB1) Y307 Uniprot
Q13480 (GAB1) Y373 Uniprot
Q13480 (GAB1) Y406 Uniprot
Q13480-1 (GAB1) Y447 Uniprot
Q13480-1 (GAB1) Y472 Uniprot
Q13480 (GAB1) Y589 Uniprot
Q13480-2 (GAB1) Y619 Uniprot
Q13480 (GAB1) Y627 Uniprot
Q13480-2 (GAB1) Y657 Uniprot
Q13480 (GAB1) Y659 Uniprot
Q13480-2 (GAB1) Y689 Uniprot
Q14457 (BECN1) Y229 Uniprot
Q14457 (BECN1) Y233 Uniprot
Q14457 (BECN1) Y352 Uniprot
Q38SD2 (LRRK1) Y971 Uniprot
Q8IVM0 (CCDC50) Y217 Uniprot
Q8IVM0 (CCDC50) Y279 Uniprot
Q8IVM0 (CCDC50) Y304 Uniprot
Q8NFJ5 (GPRC5A) Y317 Uniprot
Q8NFJ5 (GPRC5A) Y320 Uniprot
Q8NFJ5 (GPRC5A) Y347 Uniprot
Q8NFJ5 (GPRC5A) Y350 Uniprot
Q8TDY4 (ASAP3) Y34 Uniprot
Q92529-2 (SHC3) Y218 Uniprot
Q92529-2 (SHC3) Y219 Uniprot
Q92529-2 (SHC3) Y256 Uniprot
Q92529-2 (SHC3) Y257 Uniprot
Q92529-2 (SHC3) Y283 Uniprot
Q92529-2 (SHC3) Y301 Uniprot
Q92952 (KCNN1) Y109 Uniprot
Q96TA1 (FAM129B) Y593 Uniprot
Q9P0J1 (PDP1) Y381 Uniprot
Q9UBN7 (HDAC6) Y570 Uniprot
Q9UK17 (KCND3) Y136 Uniprot
Q9UKV8 (AGO2) Y393 Uniprot

Research Backgrounds

Function:

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration. Plays a role in enhancing learning and memory performance (By similarity).

Isoform 2 may act as an antagonist of EGF action.

(Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

PTMs:

Phosphorylated on Tyr residues in response to EGF. Phosphorylation at Ser-695 is partial and occurs only if Thr-693 is phosphorylated. Phosphorylation at Thr-678 and Thr-693 by PRKD1 inhibits EGF-induced MAPK8/JNK1 activation. Dephosphorylation by PTPRJ prevents endocytosis and stabilizes the receptor at the plasma membrane. Autophosphorylation at Tyr-1197 is stimulated by methylation at Arg-1199 and enhances interaction with PTPN6. Autophosphorylation at Tyr-1092 and/or Tyr-1110 recruits STAT3. Dephosphorylated by PTPN1 and PTPN2.

Monoubiquitinated and polyubiquitinated upon EGF stimulation; which does not affect tyrosine kinase activity or signaling capacity but may play a role in lysosomal targeting. Polyubiquitin linkage is mainly through 'Lys-63', but linkage through 'Lys-48', 'Lys-11' and 'Lys-29' also occurs. Deubiquitination by OTUD7B prevents degradation. Ubiquitinated by RNF115 and RNF126 (By similarity).

Palmitoylated on Cys residues by ZDHHC20. Palmitoylation inhibits internalization after ligand binding, and increases the persistence of tyrosine-phosphorylated EGFR at the cell membrane. Palmitoylation increases the amplitude and duration of EGFR signaling.

Methylated. Methylation at Arg-1199 by PRMT5 stimulates phosphorylation at Tyr-1197.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein. Endoplasmic reticulum membrane>Single-pass type I membrane protein. Golgi apparatus membrane>Single-pass type I membrane protein. Nucleus membrane>Single-pass type I membrane protein. Endosome. Endosome membrane. Nucleus.
Note: In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055).

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

Subunit Structure:

Binding of the ligand triggers homo- and/or heterodimerization of the receptor triggering its autophosphorylation. Heterodimer with ERBB2. Forms a complex with CCDC88A/GIV (via SH2-like regions) and GNAI3 which leads to enhanced EGFR signaling and triggering of cell migration; binding to CCDC88A requires autophosphorylation of the EGFR C-terminal region, and ligand stimulation is required for recruitment of GNAI3 to the complex. Interacts with ERRFI1; inhibits dimerization of the kinase domain and autophosphorylation. Part of a complex with ERBB2 and either PIK3C2A or PIK3C2B. Interacts with GRB2; an adapter protein coupling the receptor to downstream signaling pathways. Interacts with GAB2; involved in signaling downstream of EGFR. Interacts with STAT3; mediates EGFR downstream signaling in cell proliferation. Interacts with RIPK1; involved in NF-kappa-B activation. Interacts (autophosphorylated) with CBL, CBLB and CBLC; involved in EGFR ubiquitination and regulation. Interacts with SOCS5; regulates EGFR degradation through ELOC- and ELOB-mediated ubiquitination and proteasomal degradation. Interacts with PRMT5; methylates EGFR and enhances interaction with PTPN6. Interacts (phosphorylated) with PTPN6; inhibits EGFR-dependent activation of MAPK/ERK. Interacts with COPG1; essential for regulation of EGF-dependent nuclear transport of EGFR by retrograde trafficking from the Golgi to the ER. Interacts with TNK2; this interaction is dependent on EGF stimulation and kinase activity of EGFR. Interacts with PCNA; positively regulates PCNA. Interacts with PELP1. Interacts with MUC1. Interacts with AP2M1. Interacts with FER. May interact with EPS8; mediates EPS8 phosphorylation. Interacts (via SH2 domains) with GRB2, NCK1 and NCK2. Interacts with ATX2. Interacts with GAREM1. Interacts (ubiquitinated) with ANKRD13A/B/D; the interaction is direct and may regulate EGFR internalization after EGF stimulation. Interacts with GPER1; the interaction occurs in an estrogen-dependent manner. Interacts (via C-terminal cytoplasmic kinase domain) with ZPR1 (via zinc fingers). Interacts with RNF115 and RNF126. Interacts with GPRC5A (via its transmembrane domain). Interacts with FAM83B; positively regulates EGFR inducing its autophosphorylation in absence of stimulation by EGF. Interacts with LAPTM4B; positively correlates with EGFR activation. Interacts with STX19. Interacts with CD44.

Family&Domains:

Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.

Research Fields

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Adherens junction.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Gap junction.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Calcium signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Organismal Systems > Endocrine system > Estrogen signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

References

1). Resistance to anti-HER2 therapy associated with the TSC2 nonsynonymous variant c.4349 C > G (p.Pro1450Arg) is reversed by CDK4/6 inhibitor in HER2-positive breast cancer. npj Breast Cancer, 2023 (PubMed: 37160904) [IF=5.9]

Application: WB    Species: Human    Sample: BT474 cell

Fig. 3 Expression of proteins involved in the HER2/AKT/mTOR and cyclinD1/CDK4 signaling pathways in BT474 cell lines treated with lapatinib and/or palbociclib. a Western blot analysis of proteins involved in the HER2/AKT/mTOR signaling pathway after treatment with lapatinib and/or palbociclib for 48 h. b Western blot analysis of proteins involved in the cyclinD1/CDK4 signaling pathway after treatment with lapatinib and/or palbociclib for 48 h. c p-HER2 expression levels under treatment with different drugs in the same cell. d p-HER2 expression levels in TSC2-NC, WT, and MT groups treated with the same drugs. e p-TSC2 expression levels under treatment with different drugs in the same cell. f p-TSC2 expression levels in TSC2-NC, WT, and MT groups treated with the same drugs. g p-mTOR expression levels under treatment with different drugs in the same cell. h p-mTOR expression levels in TSC2-NC, WT, and MT groups treated with the same drugs. i p-P70S6K expression levels under treatment with different drugs in the same cell. j p-P70S6K expression levels in TSC2-NC, WT, and MT groups treated with the same drugs. Data are shown as mean ± SD; One-way ANOVA was used to analyze the data in (d, f, h, j). Error bars are SEM.

2). TNIK drives castration-resistant prostate cancer via phosphorylating EGFR. iScience, 2024 (PubMed: 38226156) [IF=5.8]

Application: IHC    Species: Mouse    Sample:

Figure 6 Targeting TNIK suppresses CRPC tumor progression in vivo (A) C4-2 cells were implanted subcutaneously in male BALB/c mice. When tumors became palpable, mice administered daily by oral gavage either with vehicle (10% DMSO in PBS) or NCB0846 (80 mg/kg of body weight) for 10 days (n = 4 mice for each treatment). Tumor volumes were measured with calipers. (B) Tumor size of xenografts of the above represented the growth of tumor over 10 days (n = 4) in athymic nude mice (p < 0.001). Data are shown as mean ± SD. (C) Tumor weight of the control mice tumors and NCB-0846-treated mice tumors (p < 0.001). Data are shown as mean ± SD. (D) Body weight of nude mice after implantation of control or C4-2 xenografts and treatment with vehicle or NCB-0846 for 4 weeks. (E) Quantitation of Ki-67, TNIK, p-EGFR, β-catenin, vimentin, E-cadherin, BMP6, and BMP7 expressions in C4-2 xenograft tumors from each group; specimens were got at 10 days posttreatment. Scale bars: 500 μm. The IHC was scored according to number of cells expressing the indicated proteins, and statistical analysis was performed (non-parametric Kruskal-Wallis test) in order to determine significance. Data are shown as mean ± SD.

3). Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2019 (PubMed: 31173177) [IF=5.4]

Application: WB    Species: human    Sample: H1650, H1975 and A549 cells

Figure 2.| Cell lines with different EGFR genotypes have different basal expressions of CK2 and EGFR. Western blotting images, and quantification of CK2α, EGFR and p‑EGFR protein expression. β‑actin was used as a loading control. The mean ± standard deviation was calculated for three independent experiments. CK2α, casein kinase II subunit α; EGFR, epidermal growth factor receptor; p‑, phosphorylated.

4). Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways. Toxicology and Applied Pharmacology, 2022 (PubMed: 35143806) [IF=3.8]

5). Inorganic arsenic exposure promotes malignant progression by HDAC6-mediated down-regulation of HTRA1. Journal of Applied Toxicology, 2023 (PubMed: 36861143) [IF=3.3]

Application: WB    Species: Human    Sample: Caco-2 cells

FIGURE 3 Molecular profiling for iAs-induced changes in Caco-2 cells. (A) Protein levels of claudin 3 and cofilin were determined by Western blot analysis. (B) Transcript levels of IL-6, TNF-α, and MMP13 were determined by RT-qPCR, with GAPDH as an internal control. (C) The levels of EGF in the culture supernatant were examined by ELISA. (D) A marked increase in the phosphorylated levels of EGFR, Src, AKT, and p38 was shown by Western blot analysis. RT-qPCR (E) and Western blot analysis (F) results showed the down-regulation of HTRA1 expression caused by chronic iAs exposure. Data were representatives of at least three independent experiments, shown as mean ± SD. The significance threshold for Student's t-test:

6). PTPRH Alleviates Airway Obstruction and Th2 Inflammation in Asthma as a Protective Factor. Journal of Asthma and Allergy, 2022 (PubMed: 35140475) [IF=3.2]

Application: WB    Species: Human    Sample: HBECs

Figure 7 The expression of PTPRH was induced by cytokine IL-13 and the effect of PTPRH on EGFR, ERK1/2, and AKT in HBECs. (A) The transcript levels of PTPRH and EGFR with or without IL-13 stimulation were detected by qRT-PCR. (B) The protein expression in HBECs with or without IL-13 stimulation were detected by Western blotting. (C) The protein expression in HBECs transfected with empty or PTPRH over expression vector were detected by Western blotting. (D) The protein expression in HBECs transfected with empty or PTPRH siRNA were detected by Western blotting. The transcript levels are expressed as log2 transformed and relative to the mean of control group. Data are mean ± SD. *p < 0.05; **p < 0.01.

7). Distribution pattern of invasion‑related bio‑markers in head Marjolin's ulcer. Experimental and Therapeutic Medicine, 2020 (PubMed: 32855703) [IF=2.7]

Application: WB    Species: human    Sample: MU tissue

Figure 5.| Expression levels of tumor invasion-associated cell signaling pathways molecules at different sites of Marjolin's ulcer. Relative mRNA expression levels of (A) FAK, (B) STAT3, (C) EGFR, (D) CXCL9 and (E) RANKL.Values are expressed as the mean ± standard error of the mean (n=3). Western blot was used to determine the protein level of phosphorylated STAT3, FAK and EGFR (F) and statistical analysis has been performed (G-I).

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.